The Iotron Advantage
The “Iotron Advantage” is how we describe the benefit to pharmaceutical companies, nuclear pharmacies, and research centers who source their Copper-67 (Cu-67) from Iotron.
What We Offer
Iotron pledges to be a preferred supplier of Cu-67, prioritizing Quality, Quantity, Reliability, and Support.
Team Of Experts
Iotron’s leadership team is comprised of highly skilled, highly experienced chemists, engineers and executives. The leadership represent a collective 180+ years in the radioisotope and radiopharmaceutical fields. Along with our entire team, Iotron is committed to successful partnerships and customer satisfaction by delivering the “Iotron Advantage”:
Quality, Quantity, Reliability, Support.
Patrick Donahue
Chief Executive Officer & President
Pat Donahue is a senior radiopharmaceutical executive with over 40 years of experience. Prior to Iotron he served as President and CEO of Theragnostics Inc. (now Ariceum). Pat has held leadership positions and key consulting roles at companies including Jubilant, Eckert & Ziegler, DuPont, Curium, ANSTO, Invicro, Clarity, Perspective Therapeutics, and SirTeX. Pat is a founder and past president of the Boston Chapter of the International Society for Pharmaceutical Engineering. He holds a BS and MBA in Chemical Engineering.
Steve Sugden
Chief Scientific Officer
Steve Sugden brings over four decades of expertise in the commercial applications of accelerators to his role at Iotron Medical. Steve’s career-long leadership in both public and private commercialization projects has driven innovation within the field of accelerator applications. His background in physics and his unwavering dedication to advancing the use of accelerators make him an invaluable member of the Iotron Medical leadership team. Steve has a Ph.D. in applied radiation.
Dave Hamilton
Chief Financial Officer
Dave Hamilton, Chief Financial Officer at Iotron Medical, brings 15 years of expertise from strategic financial roles in the pharmaceutical and biotech industries. Notably, he has served as a top financial executive in three oncology firms. He holds a Bachelor of Science in Finance and an MBA from Harvard University.
David Pendleton
Commercial Consultant
Dave Pendleton, a Commercial Consultant at Iotron Medical, brings over 30 years of nuclear medicine experience to his role. Dave has held numerous commercial executive positions in the fields of radiopharmaceuticals and diagnostic imaging, and most recently has spent 12 years consulting in these fields. Dave’s consulting practice spans product development, launch and commercialization. Dave holds degrees in Biology and Psychology from Northeastern University.
Michael Scott
Board Chairman
As Board Chairman of Iotron Medical, Mike Scott brings a wealth of diverse experience to his role. Mike’s background includes owning and leading multiple companies in the construction and energy sectors, and serving as a Member of Parliament in the Canadian Federal Government. He played a pivotal role in leading the successful $150 million divestment of Iotron Industries. Mike provides invaluable guidance, oversight and strategic vision to Iotron Medical.
Alan Packard
Director and Advisor
Alan Packard, Director and Advisor at Iotron Medical, is a globally recognized expert in the field of Nuclear Medicine. Alan holds the positions of Senior Research Associate, Nuclear Medicine and Molecular Imaging, Boston Children’s Hospital, and Associate Professor of Radiology, Harvard Medical School. He recently served as the President of the prestigious Society of Nuclear Medicine and Molecular Imaging. Alan holds a Bachelor of Science degree in Chemistry and a Ph.D. in Inorganic Chemistry.
Sol Rauch
Director
Sol Rauch, a Director at Iotron Medical, brings a wealth of senior level experience. His expertise in the aerospace industry spans design, program management, and market development. Sol’s tenure at the ex-Canadian Marconi Company led to more than $1 billion in sales, and his involvement in Canada’s Defense Advisory Board highlight his strategic insight and leadership capabilities. Sol served on the Board that successfully divested Iotron Industries, the parent company of Iotron Medical. Sol holds a Meng degree in electrical engineering and a master’s degree in engineering.
David Ehst
Advisor
David Ehst, an Advisor at Iotron Medical, has over 30 years of expertise in nuclear technology development. David holds patents for technology licensed by Iotron, stemming from collaborative projects both within and beyond national borders. He continues to provide invaluable guidance to Iotron. David earned a Ph.D. in nuclear engineering from MIT.
